Entero Healthcare Solutions Limited · NSE:ENTERO
Entero Healthcare Solutions — Q1 FY27 Earnings Presentation
37 slides from Entero Healthcare Solutions's earnings presentation, August 2026
Slide 1: Entero Healthcare Solutions Limited Q1FY27 Investor Presentation
Everything in Pharma… Everywhere in India… Entero Healthcare Solutions Limited Q1FY27 Investor Presentation – August 2026
Slide 2: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Entero Healthcare Solutions Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe
Slide 3: Q1 FY27 Financial Highlights
Q1 FY27 Financial Highlights
Slide 4: Management Commentary
Management Commentary We have started FY27 on a strong footing with consolidated revenue growth of 40.0% YoY on a like-for-like basis to INR 1,940 crore alongside further margin improvement with EBITDA margins reaching 5.0%. Also, return ratios have moved decisively in line, with ROCE nearly doublin
Slide 5: Q1FY27 - Key Financial Highlights
Q1FY27 - Key Financial Highlights › Revenue growth on LFL basis was 40.0% YoY. Organic revenue growth on LFL basis was 19.6% YoY. Like-for-Like growth includes impact of revenue recorded on net margin basis and divestment of a subsidiary › Reported revenue growth was 38.2% YoY. Organic revenue growt
Slide 6: Consolidated Financial Highlights
Consolidated Financial Highlights Revenue (Rs. Cr) Gross Profit (Rs. Cr) & Margin (%) +38% +59% 1,940 221 1,404 140 11.4% 9.9% Q1FY26 Q1FY27 Q1FY26 Q1FY27 EBITDA (Rs. Cr) & Margin (%) PAT (Rs. Cr) & Margin (%) +94% +72% 97 52 30 50 5.0% 3.6% 2.7% 2.2% Q1FY26 Q1FY27 Q1FY26 Q1FY27 6
Slide 7: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (INR Cr) Q1FY27 Q4FY26 Q1FY26 YoY% Revenue 1,940.5 1,909.9 1,403.8 38% Cost of Goods Sold 1,719.1 1,702.5 1,264.2 Gross Profit 221.4 207.4 139.6 59% Gross Margin (%) 11.4% 10.9% 9.9% 147 bps Employee Expenses 68.7 64.0 56.7 ESOP Expenses 0.8 0.7 0.9 O
Slide 8: Key Balance Sheet Highlights
Key Balance Sheet Highlights Net Operating Working Capital (Days) RoCE (%) RoE (%) 66 21.1% 20.4% 61 59 18.4% 16.0% 11.5% 9.0% Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 RoCE: EBIT / Average Capital Employed (Capital Employed = Tangible Networth + Borrowings + Deferred T
Slide 9: Revenue Split
Revenue Split +38.2% 20.4% 0.0% 1,940 17.8% 1,404 Q1FY26 Revenue Organic growth Calendarization New acquisitions Q1FY27 Revenue Particulars Q1FY26 Q2FY26 Q3FY26 Q4FY26 FY26 Q1FY27 Organic Growth 12.0% 10.7% 14.2% 16.6% 13.4% 17.8% Organic growth - LFL 15.0% 13.4% 17.1% 17.1% 15.6% 19.6% vs IPM growt
Slide 10: Entero's FY27 MedTech revenue expected to cross Rs. 1,000 Cr
Entero’s FY27 MedTech revenue expected to cross Rs. 1,000 Cr MedTech Industry Overview (USD bn) Strategic rationale for acquisitions in MedTech market 45-50 MedTech is large and a growing market Synergistic with Entero’s pharmaceutical distribution 13-13.5 Attractive and significant consolidation op
Slide 11: Operational Highlights
Operational Highlights Outperforming Customers Relationship with Market Growth SKU’s Handled (Retailers) healthcare product (Q1FY27) manufacturers Entero: 38% › Q1FY27: 72,000+ › Q1FY27: 83,400+ › Q1FY27: 3,000+ IPM: 14% › Q1FY26: 71,000+ › Q1FY26: 74,700+ › Q1FY26: 2,600+ Customers Districts Covere
Slide 12: Growing faster than Industry… Gaining Market Share
Growing faster than Industry… Gaining Market Share IPM Entero Organic Growth Entero Consolidated Growth 43%* 40%* 38% 37% 35% 35% 31% 31% 31%* 29%* 28%* 23%* 22% 19% 19% 19% 20% 20%* 16% 17% 17%* 17%* 15% 15% 14% 15%* 18% 17% 17% 13%* 16% 15% 11%* 14% 9% 10% 9% 12% 12% 7% 9% 12% 9% 9% 8% 7% 7% 7% 6%
Slide 13: About Us
About Us
Slide 14: We are a Healthcare Supply Chain Solutions Specialist
We are a Healthcare Supply Chain Solutions Specialist Amongst the top three healthcare products distributors in India in terms of revenue Our Warehouses Fastest scale-up of operations among healthcare products distributors in India with track record of 51 acquisitions Pan-India presence through our
Slide 15: Entero at a Glance
Entero at a Glance Geographical Reach of Distribution Network 72,000+ 2,300+ 3,000+ Customers Retail customers Hospital Supply relationships with catered to customers healthcare product manufacturers AMRITSAR PANCHKULA DEHRADUN KARNAL DELHI GHAZIABAD GURGAON NOIDA FARIDABAD JAIPUR GORAKHPUR LUCKNOW
Slide 16: Building a Highly Scalable Business Model
Building a Highly Scalable Business Model Consolidated Revenue (Rs. Cr) Customers (Retailers) Customers (Hospitals) FY23 81,400+ FY23 3,400+ FY24 86,300+ FY24 3,500+ 6,591 FY25 95,300+ FY25 3,600+ FY26 105,300+ FY26 3,600+ Relationship with healthcare 5,096 SKU’s Handled product manufacturers +30% C
Slide 17: Board of Directors: Governance is our foundation for growth
Board of Directors : Governance is our foundation for growth Prabhat Agrawal Sujesh Vasudevan Rajesh Shashikant Dalal Sandhya Gadkari Sharma Promoter, Managing Director and Chairperson and Non-Executive Non-Executive Independent Non-Executive Independent CEO Independent Director Director Director Pr
Slide 18: Leadership Team
Leadership Team Prabhat Agrawal Prem Sethi Balakrishnan Natesan Kaushik Promoter, Managing Director and CEO Promoter, Whole-time Director and COO Group Chief Financial Officer ◼ Previous experience as CEO with Alkem Laboratories, ◼ Previous experience as Director – Offering Development and ◼ Previou
Slide 19: Leadership Team
Leadership Team Abhitesh Kumar Manish Kumar Sanjay Chakraborty Gaurav Kumar Sandip Dey Sanu Kapoor Chief Growth Officer President - Central SVP - Sales & Marketing, VP - Retail President - VP - General Counsel, Company Procurement & Partnership MedTech Business Pharma Business Institutional Business
Slide 20: Market Opportunity
Market Opportunity
Slide 21: Pharmaceutical Supply Chain in India is Highly Fragmented
Pharmaceutical Supply Chain in India is Highly Fragmented Player in Value Chain Typical Functions and Role No. of Players Typical Margin range Pharmaceutical and Healthcare Companies ~3,000 Products Manufacturer ▪ Manufacturing units supplying finished products 40 – 60% Man. Units 10,500 ▪ Marketer
Slide 22: Key Challenges in the Pharmaceutical Supply Chain
Key Challenges in the Pharmaceutical Supply Chain Pharmaceutical and Healthcare Products Manufacturer / High expiries due to multiple Complexity of dealing with Limited or no secondary sales No direct reach to retailers, Inadequate storage stock points and no data Marketer multiple sub-scale distrib
Slide 23: Healthcare Products Distribution Market Overview
Healthcare Products Distribution Market Overview Large and Growing Target Addressable Market… …Led by Increasing Share of Large / National Distributors Share of the total distributor sales for Large / National pharmaceutical distributors 20-30% CAGR $33.2bn 10-11% 25-30% 8-10% Target Addressable Mar
Slide 24: Key Strengths
Key Strengths
Slide 25: Key Strengths
Key Strengths We Operate in the Large and Highly Fragmented Indian Healthcare Products Distribution Market and Expect to Benefit from Market Consolidation We are One of India’s Largest and Fastest Growing Healthcare Products Distribution Platforms Track Record of Inorganic Expansion and Integration
Slide 26: Highly Fragmented Market… to Accelerate Consolidation
Highly Fragmented Market… to Accelerate Consolidation US China India(1) Germany Top 3: 90 – 95% Top 4: 40 – 45% Top 3: 8 – 10% Top 5: 95 – 97% Share of Large Players in the Pharma Distribution Top 3 Top 4 Top 3 Top 5 / All Share of Top x 2020 90 – 95% 40 – 45% 8 – 10% 95 – 97% in Total Pharma Distri
Slide 27: One of India's Largest & Fastest Growing Healthcare Supply Chain Company
One of India’s Largest & Fastest Growing Healthcare Supply Chain Company Geographical Reach of Distribution Network Distribution Presence 19 States 45/475 Cities/Districts AMRITSAR Customer Network PANCHKULA DEHRADUN KARNAL GHAZIABAD DELHI NOIDA Retail GURGAON Hospital JAIPUR FARIDABAD GORAKHPUR LUC
Slide 28: Successful track record of Acquisitions and Integration
Successful track record of Acquisitions and Integration Track Record of Growth of Acquired Companies Acquisition Strategy Distributor Name Date of Acquisition Location FY21-23 Growth R.S.M Pharma 14-Aug-2018 Bengaluru ~69% › Take advantage of market consolidation opportunities available Getwell Medi
Slide 29: Differentiated Business Model
Differentiated Business Model Offers both demand generation and demand fulfilment capabilities to healthcare brands and product manufacturers Demand Generation via Integrated Demand Fulfilment via end-to-end healthcare products distribution solutions Commercial Solutions Deploy Medical Representativ
Slide 30: Proprietary Technology Platform
Proprietary Technology Platform with Integrated Business Intelligence Tools and Solutions Technology-Focused Approach Anchored on Our Proprietary Integrated Tech …To Grow our Operations and Bring Efficiencies in the Healthcare Platforms and Business Intelligence Tools… Products Distribution Ecosyste
Slide 31: Key Growth Drivers
Key Growth Drivers Benefit from healthcare products distribution market consolidation with strategic acquisitions Strengthen market position through increases in customer base, wallet share and geographic penetration Pursue comprehensive marketing and distribution collaborations with healthcare prod
Slide 32: Historical Financials
Historical Financials
Slide 33: Historical Financial Highlights
Historical Financial Highlights Revenue (Rs. Cr) Gross Profit (Rs. Cr) and Margin (%) 8.3% 8.1% 9.0% 9.5% 10.3% 6,591 680 +27% +34% 5,096 486 3,922 3,300 352 2,522 268 210 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 EBITDA (Rs. Cr) and Margin (%) Net Operating Working Capital (Days)* 1.0% 1.9%
Slide 34: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (INR Cr) FY26 FY25 FY24 FY23 FY22 Revenue 6,591.2 5,095.8 3,922.3 3,300.2 2,522.1 Cost of Goods Sold 5,910.8 4,609.5 3,570.4 3,031.9 2,312.4 Gross Profit 680.4 486.3 352.0 268.3 209.6 Gross Margin (%) 10.3% 9.5% 9.0% 8.1% 8.3% Employee Expenses 241.9
Slide 35: Consolidated Balance Sheet
Consolidated Balance Sheet ASSETS (Rs. Cr) Mar-26 Mar-25 Mar-24 Mar-23 Mar-22 EQUITY AND LIABILITIES (Rs. Cr) Mar-26 Mar-25 Mar-24 Mar-23 Mar-22 ASSETS Equity Non-current assets Equity Share capital 43.5 43.5 43.5 4.1 3.9 Property, plant and equipment 103.1 57.0 41.0 43.2 45.7 Other equity 1,645.1 1
Slide 36: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (Rs. Cr) FY26 FY25 FY24 FY23 FY22 Net Profit Before Tax 179.3 138.7 35.6 -3.7 -19.8 Adjustments for: Non-Cash Items / Other Investment or Financial Items 107.1 44.0 86.6 -71.2 -41.5 Operating profit before working capital changes 286.4 182.8 122.2 67.5 21
Slide 37: Investor Relations Contacts
Company: Investor Relations Advisor: CIN: L74999HR2018PLC072204 CIN: U74140MH2010PTC204285 Ms. Akanksha Gupta Mr. Jigar Kavaiya / Parin Narichania E: irentero@ehspl.com E: jigar.kavaiya@sgapl.net / parin.n@sgapl.net T: +91-22-69019100 T: +91 9920602034 / +91 9930025733 www.enterohealthcare.com www.s
Entero Healthcare Solutions — Q1 FY27 Earnings Presentation on 6ix